Document Detail

Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.
MedLine Citation:
PMID:  18341668     Owner:  NLM     Status:  MEDLINE    
AIM: To examine inter- and intrapatient variability in the pharmacokinetics of intravenous (i.v.) busulphan given as a single daily dose to children with malignant (n = 19) and nonmalignant (n = 21) disease.
METHODS: Busulphan (120 mg m(-2), 130 mg m(-2) or 3.2 mg kg(-1)) was administered over median 2.1 h. Blood samples (4-10) were collected after the first dose, busulphan concentrations were measured and pharmacokinetic parameters, including clearance (CL) and area under the concentration-time curve (AUC), were determined using the Kinetica software (Innaphase). Interpatient variability was assessed as percent coefficient of variation (% CV). Intrapatient variability was assessed by calculating percent differences between observed full dose AUC and AUC predicted from an initial 65 mg m(-2) dose in 13 children who had busulphan pharmacokinetic monitoring.
RESULTS: Clearance of i.v. busulphan in 40 children was 4.78 +/- 2.93 l h(-1) (% CV 61%), 0.23 +/- 0.08 l h(-1) kg(-1) (% CV 35%) and 5.79 +/- 1.59 l h(-1) m(-2) (% CV 27%). Age correlated significantly (p < 0.001) with CL (l h(-1)) and CL (l h(-1) kg(-1)), but not with CL (l h(-1) m(-2)). AUC normalized to the 130 mg m(-2) dose ranged from 14.1 to 56.3 mg l(-1) x h (% CV 37%) and also did not correlate with age. Interpatient variability in CL (l h(-1) m(-2)) was highest in six children with immune deficiencies (60%) and lowest in seven children with solid tumours (14%). Intrapatient variability was <13% for nine (of 13) children, but between 20 and 44% for four children.
CONCLUSIONS: There is considerable inter- and intrapatient variability in i.v. busulphan CL (l h(-1) m(-2)) and exposure that is unrelated to age, especially in children with immune deficiencies. These results suggest that monitoring of i.v. busulphan pharmacokinetics is required.
Christa E Nath; John W Earl; Nalini Pati; Katherine Stephen; Peter J Shaw
Related Documents :
20084538 - Supporting the recommended paediatric dosing regimen for rufinamide in lennox-gastaut s...
20124468 - Comparing outcomes of meropenem administration strategies based on pharmacokinetic and ...
24688148 - Pharmacokinetics of depside salts from salvia miltiorrhiza in healthy chinese volunteer...
24471748 - Use of monte carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to es...
18270838 - The expression of msi-1 and its significance in small intestinal mucosa severely damage...
11581228 - Ex vivo 12 h bactericidal activity of oral co-amoxiclav (1.125 g) against beta-lactamas...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-03-13
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  66     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-27     Completed Date:  2008-08-11     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  50-9     Citation Subset:  IM    
Departments of Biochemistry, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Alkylating / administration & dosage,  pharmacokinetics*
Area Under Curve
Bone Marrow Transplantation
Busulfan / administration & dosage,  pharmacokinetics*
Child, Preschool
Drug Administration Routes
Immunosuppressive Agents / administration & dosage,  pharmacokinetics*
Observer Variation
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Immunosuppressive Agents; 55-98-1/Busulfan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Noninvasive biophysical assessments of the efficacy of a moisturizing cosmetic cream base for patien...
Next Document:  Absence of respiratory effects with ivabradine in patients with asthma.